General Archives - Page 2 of 2 - Korecyte Bio

Home
About us
- Management
- Advisors
Our science
- Technology
- Pipeline
Careers
- Latest vacancies
Partners & Investors
- Partners
- Investors
News
- Latest news
Contact us
- General enquiries
- Business development

Korecyte Bio is an international biotech startup based between the Netherlands and United Kingdom that was established in 2023. Our mission is to develop next-generation CAR-T cellular immunotherapies

Korecyte’s CSO to present at October’s Cell & Gene Therapy days in Germany

Korecyte Bio is an international biotech startup based between the Netherlands and United Kingdom that was established in 2023. Our mission is to develop next-generation CAR-T cellular immunotherapies

Korecyte attending Biotechgate Partnering Q3 2023

Korecyte Bio is an international biotech startup based between the Netherlands and United Kingdom that was established in 2023. Our mission is to develop next-generation CAR-T cellular immunotherapies

Dr. Arnold webinar about HypoxiCAR

Korecyte Bio is an international biotech startup based between the Netherlands and United Kingdom that was established in 2023. Our mission is to develop next-generation CAR-T cellular immunotherapies

Commercial agreement signed

Previous 1 2

Site navigation

Home
Management
Technology
Pipeline
Vacancies
Partners and Investors
News
Contact us
Privacy policy
Cookie statement

Location

Korecyte Bio Ltd.
33 Cavendish Square
London W1G 0PW
United Kingdom

About Korecyte Bio

We understand the hardships that cancer patients and their loved ones face, which is why we are committed to developing the next-generation CAR-T therapy that is safe and effective for treating solid tumours. Join us in our mission to eradicate cancer and provide hope to millions of patients worldwide.

Contact details

General inquiries: info@korecyte.com.

In case you have a collaboration project to discuss, reach out to business development at: BD@korecyte.com.

X

LinkedIn

This website uses cookies to ensure that you have the best experience. If you continue to use this site we will assume that you agree to this.